Literature DB >> 16272158

Binding of PAI-1 to endothelial cells stimulated by thymosin beta4 and modulation of their fibrinolytic potential.

Joanna Boncela1, Katarzyna Smolarczyk, Elzbieta Wyroba, Czeslaw S Cierniewski.   

Abstract

Our previous studies showed that thymosin beta4 (Tbeta4) induced the synthesis of plasminogen activator inhibitor-1 (PAI-1) in cultured human umbilical vein endothelial cells (HUVECs) via the AP-1 dependent mechanism and its enhanced secretion. In this work we provide evidence that the released PAI-1 is accumulated on the surface of HUVECs, exclusively in its active form, in a complex with alpha1-acid glycoprotein (AGP) that is also up-regulated and released from the cells. This mechanism is supported by several lines of experiments, in which expression of both proteins was analyzed by flow cytometry and their colocalization supported by confocal microscopy. PAI-1 did not bind to quiescent cells but only to the Tbeta4-activated endothelial cells. In contrast, significant amounts of AGP were found to be associated with the cells overexpressing enhanced green fluorescent protein (EGFP)-alpha1-acid glycoprotein (AGP) without Tbeta4 treatment. The AGP.PAI-1 complex was accumulated essentially at the basal surface of endothelial cells, and such cells showed (a) morphology characteristic for strongly adhered and spread cells and (b) significantly reduced plasmin formation. Taken together, these results provide the evidence supporting a novel mechanism by which active PAI-1 can be bound to the Tbeta4-activated endothelial cells, thus influencing their adhesive properties as well as their ability to generate plasmin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272158     DOI: 10.1074/jbc.M506303200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation.

Authors:  Yun Sok Lee; Jin Woo Choi; Injae Hwang; Joo Won Lee; Jae Ho Lee; A Young Kim; Jin Young Huh; Young Jun Koh; Gou Young Koh; Hee Jung Son; Hiroaki Masuzaki; Kikuko Hotta; Assim A Alfadda; Jae Bum Kim
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

2.  Treatment of traumatic brain injury with thymosin β₄ in rats.

Authors:  Ye Xiong; Asim Mahmood; Yuling Meng; Yanlu Zhang; Zheng Gang Zhang; Daniel C Morris; Michael Chopp
Journal:  J Neurosurg       Date:  2010-05-21       Impact factor: 5.115

3.  Proteomic analysis permits the identification of new biomarkers of arterial wall remodeling in hypertension.

Authors:  Sandrine Delbosc; Mounsif Haloui; Liliane Louedec; Morgan Dupuis; Myriam Cubizolles; Vladimir N Podust; Eric T Fung; Jean-Baptiste Michel; Olivier Meilhac
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

4.  Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.

Authors:  Yiqin Zuo; Bongkwon Chun; Sebastian A Potthoff; Naj Kazi; Tyler J Brolin; Diclehan Orhan; Hai-Chun Yang; Li-Jun Ma; Valentina Kon; Timo Myöhänen; Nour-Eddine Rhaleb; Oscar A Carretero; Agnes B Fogo
Journal:  Kidney Int       Date:  2013-06-05       Impact factor: 10.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.